Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology

Viral Immunology

Volumn 16, Issue 2, 2003, Pages 159-168

  Rocha Zavaleta, L ^a,e   Pereira Suarez, A L ^b   Yescas, G ^c   Cruz Mimiaga, R M ^c   Garcia Carranca, A ^a,d   Cruz Talonia, F ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; VIRUS DNA;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE GENITAL TRACT INFECTION; GENE AMPLIFICATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PREVALENCE; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX MUCOSA; VIRUS DETECTION; VIRUS INFECTION; VIRUS TYPING; WART VIRUS;

DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MIRIDAE;

EID: 0038719829     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/088282403322017893     Document Type: Article

References (38)

1. Ahdieh, L., R.S. Klein, R. Burk, et al. 2001. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J. Infect. Dis. 184:682-690.
2. Andrade, L.A., N. Oyakawa, and J. Vassallo. 1991. Immunohistochemical demonstration of papillomavirus infection in condylomatous and preneoplastic lesions of the lower female genital tract. Pathologica 83:301-306.
3. Bontkes, H.J., T.D. de Gruijl, J.M.M. Walboomers, et al. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV16. J. Gen. Virol. 80:409-417.
4. Bosch, F.X., M.M. Manos, N. Muñoz, et al. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer. Inst. 87:796-802.
5. Bukawa, H., K.I. Sekigawa, K. Hamajima, et al. 1995. Neutralization of HIV-1 by secretory IgA induced by oral immunization by a new macromolecular multicomponent peptide vaccine candidate. Nat. Med. 1:681-685.
6. Chua, K., F. Wiklund, P. Lenner, et al. 1996. A prospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int. J. Cancer 68:54-59.
7. Clavel, C., M. Masure, J.P. Bory, et al. 1999. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br. J. Cancer. 80:1306-1311.
8. Cubie, H.A., M. Plumstead, W. Zhang, et al. 1998. Presence of antibodies to human papillomavirus-like particles (VLPs) in 11-13-year-old schoolgirls. J. Med. Virol. 56:210-216.
9. De Gruijl, T.D., H.J. Bontkes, J.M.M. Walboomers, et al. 1997. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J. Natl. Cancer. Inst. 89:630-638.
10. Dillner, J., I. Kallings, C. Brihmer, et al. 1996. Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J. Infect. Dis. 173:1394-1398.
11. Ferenczy, A., and A.B. Jenson. 1996. Tissue effects and host response. The key to the rational triage of cervical neoplasia. Obstet. Gynecol. Clin. North Am. 23:759-782.
12. Hagensee, M.E., L.A. Koutsky, S.K. Lee, et al. 2000. Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J. Infect. Dis. 181:1234-1239.
13. Ho, G.Y., R.D. Burk, I. Fleming, et al. 1994. Risk of genital human papillomavirus infection in women with human immunodeficiency virus-induced immunosuppression. Int. J. Cancer 56:788-792.
14. Hording, U., J. Junge, C. Rygaard, et al. 1995. Management of low-grade CIN: follow-up or treatment? Eur. J. Obstet. Reprod. Biol. 62:49-52.
15. Karlsen, F., M. Kalantari, A. Jenkins, et al. 1996. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J. Clin. Microbiol. 34:2095-2100.
16. Kaye, J.N., J. Cason, F.B. Pakarian, et al. 1994. Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J. Med. Virol. 44:415-421.
17. Kjaer, S.K., B. Chackerian, A.J. van den Brule, et al. 2001. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol. Biomarkers Prev. 10:101-106.
18. Kumar, B., R. Gupta, and S. Sehgal. 1991. Correlation of HPV antigen and type of genital warts with atypia. Genitourin. Med. 67:146-148.
19. Lungu, D., X. Sun, J. Felix, et al. 1992. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA 267:2493-2496.
20. Manos, M.M., Y. Ting, D.K. Wright, et al. 1989. The use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 7:209-214.
21. Marais, D.J., J.M. Best, R.C. Rose, et al. 2001. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J. Med. Virol. 65:149-154.
22. Mazanec, M.B., C.S. Kaetzel, M.E. Lamm, et al. 1992. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc. Natl. Acad. Sci. U.S.A. 89:6901-6905.
23. Parr, E.L., and M.B. Parr. 1997. Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 71:8109-8115.
24. Riethmuller, D., C. Gay, X. Bertrand, et al. 1999. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colopscopy determined by hybrid capture II and polymerase chain reaction. Diagn. Mol. Pathol. 8:157-164.
25. Rocha-Zavaleta, L., T. Barrios, A. Garcia-Carranca, et al. 2001. Cervical secretory immunoglobulin A to human papillomavirus type 16 (HPV16) from HPV 16-infected women inhibit HPV 16 virus-like particles-induced hemagglutination of mouse red blood cells. FEMS Immunol. Med. Microbiol. 31:47-51.
26. Rocha-Zavaleta, L., A. Garcia-Carranca, A. Lira, et al. 2002. Molecular evaluation of the incidence of oncogenic human papillomavirus genotypes in cervical acetowhite lesions. Intervirology 45:111-114.
27. Saiki, R.A., T.L. Bugawan, G.T. Horn, et al. 1986. Analysis of enzymatically amplified β-globin and HLA DQ alpha DNA with allele specific oligonucleotide probes. Nature 324:163-166.
28. Sasagawa, T., H. Yamazaki, Y.Z. Dong, et al. 1998. Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int. J. Cancer 75:529-535.
29. Silins, I., Z. Wang, E. Avall-Lundqvist, et al. 1999. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J. Gen. Virol. 80:2931-2936.
30. Slifka, M.D., and R. Ahmed. 1996. Long-term humoral immunity against viruses: revisiting the issue of plasma cell longevity. Trends Microbiol. 4:394-400.
31. Solomon, D. 1989. The 1988 Bethesda system for reporting cervical/vaginal cytological diagnosis. JAMA 262:931-934.
32. Tjiong, M.Y., K. Zumbach, J.T. Schegget, et al. 2001. Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia. Viral Immunol. 14:415-424.
33. Veress, G., J. Konya, T. Csiky-Meszaros, et al. 1994. Human papillomavirus DNA and anti-HPV secretory IgA antibodies in cytologically normal cervical specimens. J. Med. Virol. 43:201-207.
34. Walboomers, J.M.M., M.V. Jacobs, and M.M. Manos. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
35. Wang, Z., B. Hansson, O. Forslund, et al. 1996. Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA. J. Clin. Microbiol. 34:3056-3062.
36. Wang, Z., L. Kjellberg, H. Abdalla, et al. 2000. Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids. J. Infect. Dis. 181:456-462.
37. Wideroff, L., M. Schiffman, P. Haderer, et al. 1999. Seroreactivity of human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J. Infect. Dis. 180:1424-1428.
38. Wools, K., J.T. Bryan, B.P. Katz, et al. 1994. Detection of human papillomavirus L1 protein in condylomata acuminata from various anatomical sites. Sex. Transm. Dis. 21:103-106.